Clinical Trials | February 25, 2026
Novo Nordisk unveils weight-loss data from REDEFINE 4 trial
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB
If approved, DTX401 would be the first treatment to address the disease at its root cause
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
Under the deal, Quiver will receive an undisclosed advance payment and research support
The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
Subscribe To Our Newsletter & Stay Updated
